Skye Bioscience, Inc. (SKYE)
NASDAQ: SKYE · Real-Time Price · USD
3.950
-0.160 (-3.89%)
Sep 29, 2025, 3:20 PM EDT - Market open
Skye Bioscience Stock Forecast
Stock Price Forecast
The 4 analysts that cover Skye Bioscience stock have a consensus rating of "Strong Buy" and an average price target of $14.75, which forecasts a 273.42% increase in the stock price over the next year. The lowest target is $10 and the highest is $20.
Price Target: $14.75 (+273.42%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Aug 15, 2025.
Analyst Ratings
The average analyst rating for Skye Bioscience stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 6 | 6 | 5 | 5 | 6 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 6 | 6 | 7 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Evercore ISI Group | Evercore ISI Group | Buy Initiates $10 | Buy | Initiates | $10 | +153.16% | Aug 15, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $15 | Buy | Reiterates | $15 | +279.75% | Jun 24, 2025 |
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $18 → $14 | Strong Buy | Maintains | $18 → $14 | +254.43% | Mar 21, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $15 | Buy | Reiterates | $15 | +279.75% | Mar 21, 2025 |
| William Blair | William Blair | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Feb 28, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.39
from -0.73
EPS Next Year
-1.34
from -1.39
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | |||
| Avg | n/a | n/a | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.18 | -0.78 | |||
| Avg | -1.39 | -1.34 | |||
| Low | -1.66 | -1.90 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.